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Abstract
Purpose Recent reviews have questioned the efficacy of selective serotonin reuptake inhibitors (SSRIs) above placebo 
response, and their working mechanisms remain unclear. New approaches to understanding the effects of SSRIs are necessary 
to enhance their efficacy. The aim of this study was to explore the possibilities of using cross-sectional network analysis to 
increase our understanding of symptom connectivity before and after SSRI treatment.
Methods In two randomized controlled trials (total N = 178), we estimated Gaussian graphical models among 20 symp-
toms of the Beck Depression Inventory-II before and after 8 weeks of treatment with the SSRI paroxetine. Networks were 
compared on connectivity, community structure, predictability (proportion explained variance), and strength centrality (i.e., 
connectedness to other symptoms in the network).
Results Symptom severity for all individual BDI-II symptoms significantly decreased over 8 weeks of SSRI treatment, 
whereas interconnectivity and predictability of the symptoms significantly increased. At baseline, three communities were 
detected; five communities were detected at week 8.
Conclusions Findings suggest the effects of SSRIs can be studied using the network approach. The increased connectivity, 
predictability, and communities at week 8 may be explained by the decrease in depressive symptoms rather than specific 
effects of SSRIs. Future studies with larger samples and placebo controls are needed to offer insight into the effects of SSRIs.
Trial Registration The trials described in this manuscript were funded by the NIMH.
Pennsylvania/Vanderbilt study:
5 R10 MH55877 (https ://proje ctrep orter .nih.gov/proje ct_info_descr iptio n.cfm?aid=61866 33&icde=28344 168&ddpar 
am=&ddval ue=&ddsub =&cr=1&csb=defau lt&cs=ASC&MMOpt =).
Washington study:
R01 MH55502 (https ://proje ctrep orter .nih.gov/proje ct_info_descr iptio n.cfm?aid=20346 18&icde=28344 217&ddpar 
am=&ddval ue=&ddsub =&cr=5&csb=defau lt&cs=ASC).
Keywords Selective serotonin reuptake inhibitors · Major depressive disorder · Network analysis · Gaussian graphical 
models (GGM) · Antidepressant treatment
Introduction
Currently, selective serotonin reuptake inhibitors (SSRIs) 
are recommended as the first treatment of choice by the 
American Psychiatric Association (APA) and the National 
Institute of Clinical Excellence (NICE) for patients with 
major depressive disorder (MDD) [1, 2]. However, recent 
reviews have questioned the efficacy of SSRIs [3–5]. Given 
that there is a substantial proportion of patients who do not 
seem to benefit from acute antidepressant treatment [6], 
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it is important to increase our understanding of the way 
SSRIs work so as to enhance their efficacy.
A relatively novel conceptual and statistical approach 
may provide an interesting framework to study the work-
ing mechanisms of SSRIs. The network approach concep-
tualizes symptoms of depression as part of a network of 
co-occuring symptoms that interact to create the symptom 
profile that is termed depression [7]. Instead of assuming 
that symptoms passively originate from a common cause 
(e.g., depression), the network approach proposes a focus 
on how individual symptoms are related to each other [8]. 
The network approach is thus fundamentally different 
from the routine modus operandi of monitoring treatment 
response at the aggregate level based on a large number 
of disparate psychiatric symptoms that are added up to a 
sum-score, which may obfuscate important insights [9]. 
The network approach also can help to identify ‘central’ 
symptoms—symptoms that often co-occur with other 
symptoms and thus are assumed to easily trigger or be 
triggered by other symptoms [10].
Prior studies that have used network analysis to charac-
terize symptom patterns in depressed patients have yielded 
interesting results. Loss of energy and anhedonia appear 
to be central symptoms in analyses of both cross-sectional 
data and dynamic data using experience sampling meth-
odology (ESM), the latter of which allows for the study of 
predictive effects of the symptoms on each other [11–13]. 
Further, depressed patients appear to have increased net-
work connectivity or denser networks in cross-sectional 
data when compared to remitted patients [14] and in 
dynamic data when compared to healthy controls [15], 
suggesting that once one symptom is present, other symp-
toms might be easily triggered. However, in studies fol-
lowing patients at consecutive time points, the opposite 
pattern has been found: increased network connectivity 
when depressive symptom severity decreases [16].
With regard to potential effects of antidepressant treat-
ment, only two studies examined the effects of antidepres-
sants on the network structure of depressive symptoms. A 
recent study using dynamic data could not find evidence 
that the tricyclic antidepressant imipramine changed the 
dynamic associations between mental states [17]. In the 
STAR*D sample, using cross-sectional data, sad mood 
was found to be the most central symptom after several 
weeks of treatment with the SSRI citalopram [18]. How-
ever, the absence of a pretreatment condition, where no 
SSRI treatment was administered yet, limits insight into 
the effects of SSRIs.
Until now, the network approach has not been applied 
to explore the relationships among depressive symptoms 
before and after SSRI treatment. Such an approach may offer 
insight into the interrelations among symptoms before and 
after SSRI treatment and thus yield interesting directions for 
further study of how SSRIs may exert their effects. There-
fore, the present study aimed to explore the possibilities 
of using cross-sectional network analysis before and after 
SSRI treatment by looking at the most recent and insight-
ful network metrics. Specifically, we will examine (1) the 
interrelations, community structure, and connectivity of 
depression symptoms and (2) their centrality and predicta-
bility estimates in acutely depressed patients treated with the 
SSRI paroxetine, a commonly prescribed antidepressant. We 
combined the data of two large randomized controlled trials 
(RCTs) comparing paroxetine to pill-placebo and psycho-
logical treatment to retain sufficient power for the analyses. 
Focusing on the patients treated with paroxetine (N = 178), 
we constructed networks before the start of treatment and 
after 8 weeks of treatment. We compared the two resulting 
networks and their metrics to explore the possibilities of net-
work analysis for increasing our understanding of symptom 
connectivity before and after SSRI treatment.
Methods
Participants
Patients with moderate to severe major depressive disor-
der participated in one of two similar RCTs for treatment 
of MDD in the United States, which were combined to 
increase statistical power [19, 20]. To be included, patients 
had to (1) fulfill the DSM-IV criteria for MDD, as assessed 
by the Structured Clinical Interview for the DSM-IV [21], 
(2) 18–70 years of age, (3) English speaking, (4) and will-
ing and able to give informed consent. The first RCT, con-
ducted at the University of Pennsylvania and Vanderbilt 
University (N = 240) between 1996 and 2001, only enrolled 
moderate to severely depressed patients (17-item Ham-
ilton Rating Scale for Depression (HRSD-17) [22] ≥ 20). 
The second RCT, conducted at the University of Washing-
ton (N = 241), enrolled patients between 1998 and 2001 
and included mildly, moderately, and severely depressed 
patients (Beck Depression Inventory (BDI-II) [23] ≥ 20 and 
HRSD-17 ≥ 14).
Patients were excluded in both trials if they had a life-
time diagnosis of psychosis, bipolar disorder, organic brain 
syndrome, or mental retardation. Further excluded were 
patients presenting with imminent suicide risk requiring 
immediate hospitalization, a current Axis I disorder judged 
to be primary, substance abuse, or antisocial, borderline, 
or schizotypal personality disorder. Lastly, participants who 
had not responded favorably to an adequate trial of either CT 
or paroxetine were excluded. The studies were conducted 
in accordance with the Declaration of Helsinki and institu-
tional review boards of each of the three study sites approved 
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the study protocols. All patients provided written informed 
consent.
Treatment
The present study focuses on patients randomized to anti-
depressant medication (see Fig. 1), given our assumption 
that different treatments have different working mechanisms. 
Unfortunately, power was insufficient to construct separate 
networks for the other trial conditions. Patients randomized 
to one of the pill conditions were treated with the SSRI par-
oxetine or pill-placebo for 8 weeks in a double-blind manner. 
All patients receiving SSRI or pill-plabceo received weekly 
sessions with their prescribing clinician for the first 4 weeks 
and every other week thereafter. These sessions consisted of 
medication management, which involved education, adjust-
ment of dosage and dosage schedules, and discussions of 
adverse effects, and of clinical management, which involved 
a review of the patient’s functioning in major life domains, 
brief supportive counseling, and limited advice giving [24]. 
The usage of specific psychotherapy techniques was not 
allowed.
Measures
The BDI-II, a widely used self-report questionnaire with 
adequate psychometric properties [23, 25], was administered 
at baseline (before the start of treatment) and week 8 (mid-
treatment). Each item is rated on a 4-point Likert scale, rang-
ing from 0 to 3. Networks were constructed of 20 of the 21 
individual items of the BDI-II at each time point. The BDI-II 
item on suicidal thoughts or wishes was removed from the 
network estimations given its low variance and positively 
skewed distribution [26] (see Supplementary Materials).
Statistical analyses
Missing data
The individual SSRI treatment arms of each trial were not 
sufficiently large to estimate networks due to the large num-
ber of individual symptoms. We, therefore, combined the 
data from the Pennsylvania/Vanderbilt and Washington stud-
ies, resulting in a total of 220 patients randomized to SSRI 
treatment. Of those, 42 participants dropped out prior to 
week 8. To ensure both networks consisted of the same peo-
ple, those 42 participants were removed from the network 
analyses, resulting in a final sample of 178 participants at 
both time points. Seven individuals had partially missing 
data. The Gaussian graphical models (GGM) were estimated 
on the full data set (N = 178) using pairwise complete obser-
vations (i.e., using all available information from all par-
ticipants) [27]. Analyses of predictability and the network 
comparison test cannot deal with missing data, reducing the 
analytic data from 178 to 171 participants for those analyses.
Network estimation
First, we used the R-package qgraph (version 1.4.4) to esti-
mate the network structures of the 20 BDI-II symptoms 
at baseline and at week 8 [28]. Networks contain nodes 
Pennsylvania/ 




























Final sample without 
drop-outs prior to week 
8
(N=178)
Fig. 1  Overview of flow of participants throughout the two trials
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(symptoms) and edges (cross-sectional associations among 
symptoms). We estimated GGMs in which the edges repre-
sent partial correlation coefficients. To reduce false-positive 
edges, we applied the least absolute shrinkage and selec-
tion operator (lasso) [29]. This procedure penalizes very 
small edges by setting them to zero. The shrinkage param-
eter is chosen to minimize the extended Bayesian Informa-
tion Criterion (EBIC) parameter [30] and has been shown 
to accurately recover underlying network structures [11]. 
We applied a conservative graphical tuning parameter of 
0.5; false-positive edges are very unlikely, while very small 
actual edges may not be captured. Position of the nodes in 
the networks was initially based on the Fruchterman–Rein-
gold algorithm, which places the nodes with stronger and/
or more connections closer together [31]. We averaged the 
layout of the networks to facilitate visual comparison of the 
time points. To examine robustness of our findings, we com-
pared the standard deviations (SDs) of the BDI-II sum score 
and all individual BDI-II items between the two time points 
by means of Levene’s test (corrected for chance capitaliza-
tion by the conservative Bonferroni–Holm method). If SDs 
change significantly, differences in the network structure 
might be a result of increased variation [32].
Communities
Within the GGMs as specified above, we explored the way 
nodes within the networks cluster together through explora-
tory graph analysis (EGA) [33]. Nodes that cluster together 
in communities may be part of the same latent variable or 
dimension. EGA estimates communities in networks via a 
random walk algorithm (walktrap).
Connectivity
Network connectivity (or density) for each network was cal-
culated by summing all absolute edge weights. The differ-
ence in network connectivity for baseline and week 8 was 
tested for significance via the R-package network compari-
son test (NCT), which uses permutation testing to compare 
networks [34].
Centrality
Strength centrality was calculated for all symptoms at base-
line and week 8 by summing the absolute values of the edges 
of a given node to other nodes [10]. The higher the strength 
centrality, the more strongly is this symptom connected to 
other symptoms. The stability of strength centrality was cal-
culated at baseline and week 8 through the correlation sta-
bility coefficient (CS-coefficient), which is a method based 
on bootstraps (N = 1000) using the R-package bootnet [35]. 
The CS-coefficient represents the maximum proportion of 
cases that can be dropped, such that with 95% probability 
the correlation between the original strength centrality esti-
mates and the bootstrapped estimates is 0.7 or higher [35]. 
The higher the CS-coefficient, the more reliable the inter-
pretation of the order of centrality estimates. The R-package 
bootnet was further used to test strength centrality among 
nodes for significance at baseline and week 8.
Predictability
We further estimated the predictability of each of the nodes 
in the network, which is an estimate of how much of the var-
iance of a node is explained by neighboring nodes [36]. The 
R-package mgm [37] was used to estimate the proportion of 
explained variance for each node, which could range from 
zero (a node cannot be predicted by other nodes in the net-
work) to one (a node is perfectly predicted by other nodes).
Results
Participant characteristics
Table 1 depicts the demographic and clinical characteristics 
of the two study samples and the combined sample. The 
RCT samples were found to be quite similar with a few 
exceptions indicating that the Pennsylvania/Vanderbilt study 
included a more severely depressed sample as is appropriate 
given the inclusion criteria. BDI-II scores at baseline did 
not differ significantly between the two studies and percent 
change of BDI-II sum-scores from baseline to week 8 was 
similar (Pennsylvania/Vanderbilt study: 56.4%; Washington 
study: 56.1%), as was the percent of missing data (Pennsyl-
vania/Vanderbilt: 20.8%; Washington: 25%).
Means and variation of all 21 BDI‑II symptoms
In the combined sample, mean BDI-II sum score decreased 
significantly after 8 weeks by 44% (W = 26,052, p < .001). 
Further, as depicted in Table 2, mean scores for all indi-
vidual BDI-II items decreased significantly as well (p values 
were corrected for chance capitalization via the conserva-
tive Bonferroni–Holm method). Loss of interest in sex (30% 
change) and appetite (38%) changed the least, whereas the 
largest changes were evident in suicidal ideation (74%), 
crying (72%), and feelings of punishment (70%). SD of the 
BDI-II sum score did not change significantly after 8 weeks 
of SSRI treatment (Levene’s test = 1.34, p = .25). Five SDs 
of the individual BDI-II items decreased significantly (pun-
ishment feelings, suicidality, crying, sleep, and irritability) 
and two increased (self-dislike and concentration difficulty).
Social Psychiatry and Psychiatric Epidemiology 
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Network connectivity and community detection
Figure 2 displays the GGM networks of the 20 BDI-II symp-
toms at baseline and week 8 (N = 178). The network for 
week 8 showed significantly higher connectivity: the sum 
of all edges was 9.1 compared to 7.3 for the baseline network 
(p = 0.02).
At baseline, three symptom communities emerged: (1) 
a cluster of cognitive symptoms such as worthlessness, but 
also sad mood (orange nodes), (2) an affective behavioral 
cluster of symptoms such as loss of pleasure, energy, and 
agitation (blue), and (3) a cluster of sleep and appetite symp-
toms (green).
After 8 weeks of SSRI treatment, five communities 
emerged. The sleep and appetite cluster remained (orange 
nodes). The cognitive cluster also remained but lost symp-
toms of sad mood and crying (green). Three other clusters 
were identified: a cluster of irritation, agitation, and cry-
ing (yellow), a cluster of fatigue and loss of energy (pink), 
and an affective behavioral cluster of symptoms such as sad 
mood, loss of interest, and agitation (blue).
Symptom centrality and predictability
Figure 3 shows bootstrapped difference tests of strength 
centrality between nodes within the baseline network and 
the week 8 network (N = 178). At baseline, the most central 
symptom was loss of energy. Loss of energy showed a signif-
icantly higher strength centrality than nine other symptoms. 
In contrast, sleep had the lowest strength centrality and was 
significantly more weakly connected than 12 other symp-
toms. Mean severity of the symptoms was strongly associ-
ated with strength centrality (r = 0.69, p < 0.001), indicating 
that symptoms with higher severity were also more strongly 
interconnected.
At week 8, sleep remained the most weakly connected 
symptom; the most central symptom was loss of inter-
est. However, no symptoms showed significantly stronger 
connections than other nodes in the network. Strength 
centrality (r = 0.33, p = 0.23) was no longer associated 
with mean symptom severity. The CS-coefficient was 
0.13 for both baseline and week 8. This indicates the 
centrality estimates need to be interpreted with caution.
Finally, the overall proportion of explained variance 
(predictability) of nodes increased significantly from 
0.21 at baseline to 0.45 at week 8 (t = − 8.6, p < 0.001). 
At baseline, worthlessness and loss of energy showed the 
largest predictability relative to the other nodes; whereas 
Table 1  Demographic and clinical characteristics before randomization to SSRI treatment
Descriptive statistics represent mean (SD) unless otherwise stated. The table only includes individuals without missing data
P values represent tests between the two studies and were corrected for chance capitalization with the Bonferroni–Holm method
BDI-II Beck Depression Inventory-II, HDRS-17 17-item Hamilton Depression Rating Scale, ns non-significant
Variable Combined sample 
(N = 170)
Pennsylvania/Vanderbilt 
study (N = 95)
University of Washington 
study (N = 75)
P value
Female, N (%) 93 (55%) 56 (59%) 54 (72%) < 0.001
Caucasian, N (%) 140 (82%) 81 (85%) 59 (79%) n.s
Age 40.0 (10.9) 40.7 (11.3) 39.1 (10.4) n.s
Married/cohabitating, N (%) 66 (39%) 41 (43%) 25 (33%) n.s
Employed, N (%) 135 (79%) 84 (88%) 51 (68%) 0.018
Chronic MDD, N (%) 85 (50%) 56 (59%) 29 (39%) n.s
Age of onset 23.8 (12.5) 21.0 (12.4) 27.3 (11.9) 0.001
Number of previous episodes 1.9 (2.5) 2.7 (3.0) 1.0 (1.3) < 0.001
Duration of current episode (months) 48.4 (74.5) 52.6 (77.1) 43.2 (71.2) n.s
History of psychiatric hospitalization, N (%) 15 (9%) 10 (11%) 5 (7%) n.s
Axis I comorbidity, N (%) 91 (54%) 71 (75%) 20 (27%) < 0.001
Axis II comorbidity, N (%) 65 (38%) 50 (53%) 15 (20%) < 0.001
BDI-II score baseline 31.6 (8.9) 31.2 (9.8) 32.1 (7.6) n.s
BDI-II score week 8 13.8 (10.2) 13.6 (10.6) 14.1 (9.8) n.s
HRSD-17 score baseline 22.3 (3.9) 23.8 (3.2) 20.4 (4.0) < 0.001
HRSD-17 score week 8 12.3 (6.7) 12.4 (6.7) 12.2 (6.7) n.s
Daily dosage of paroxetine baseline 12.2 (2.7) 14.0 (4.9) 10.0 (0) –
Daily dosage of paroxetine week 8 35.7 (11.2) 38.8 (11.0) 31.7 (11.5) –
 Social Psychiatry and Psychiatric Epidemiology
1 3
for week 8, these were loss of interest and fatigue. The 
correlation between the predictability of the two time 
points was 0.76 (p < 0.001), indicating that if a node has 
high predictability at baseline, it tends to also have a high 
predictability at week 8. As expected, strength centrality 
was strongly related to the predictability of nodes at base-
line (r = 0.73, p < 0.001) and week 8 (r = 0.80, p < 0.001), 
suggesting that if a node is strongly connected to other 
variables, it tends to be predicted by other nodes as well. 
Finally, although predictability was related to mean symp-
tom severity at baseline (r = 0.68, p < 0.001), they were 
not significantly related at week 8 (r = 0.44, p = 0.053).
Discussion
This study examined changes in the relationships among 
depressive symptoms after 8 weeks of SSRI treatment 
in a sample of outpatients treated for moderate to severe 
depression. To our knowledge, this is the first study 
to compare network structures before and after SSRI 
treatment.
The severity of all individual depressive symptoms 
significantly decreased after 8 weeks of paroxetine treat-
ment and they became more strongly associated. The latter 
finding contrasts with previous network studies reporting 
that increased network connectivity is associated with 
acute depression [14, 15], but is consistent with findings 
of increased network connectivity paralleling decreases in 
symptom severity [16, 38, 39]. Corresponding to a large 
body of literature on the factor solution of the BDI-II [13, 
23, 40, 41], we found a cluster consisting of cognitive 
symptoms both at baseline and week 8. However, the affec-
tive behavioral cluster usually also reported was split into 
several separate clusters in our sample, which also differed 
somewhat across the two time points.
Based on network theory, one would expect network 
connectivity to decrease as symptoms are alleviated; when 
symptoms become more weakly connected, they may be 
less easily triggered by other symptoms [7]. Our findings 
that network connectivity increased after depressive symp-
toms decreased during SSRI treatment, therefore, seems 
counterintuitive. However, previous studies with con-
trasting findings used between-subject rather than within-
subject designs; van Borkulo et al. compared baseline 
networks of participants with persistent depression to par-
ticipants who later remitted [14], and Pe et al. compared 
depressed patients versus healthy controls using dynamic 
data [15]. The present study examined connectivity over 
time within the same participants, which may explain the 
difference in results.
Indeed, our pattern of results, increased network con-
nectivity as symptom severity decreased, is highly con-
sistent with previous studies reporting a different network 
structure paralleling a decrease in symptom severity [16, 
38, 39]. Fried et al. have suggested this pattern of results 
may have several possible explanations [16]. First, inter-
pretation of items (of the BDI-II) may change due to psy-
chological treatment, which is termed response bias. This 
seems less likely in our sample, given that our sample did 
not receive psychological treatment. Second, variability of 
symptoms may change over time, explaining differences in 
network connectivity [32]. Although the standard devia-
tions of the BDI-II individual items did not change signifi-
cantly for 14 of the 20 items used in the network analyses, 
the proportion of increased variance (predictability) did 
increase at week 8. Finally, the hypothesis that increased 
network connectivity may be the result of SSRI treatment 
seems less likely, given parallel findings in other samples 
in which not all participants were on antidepressant medi-
cation [16, 38, 39]. Unfortunately, the lack of a control 
Table 2  Overview of means and standard deviations of the individual 
BDI-II items for baseline and week 8 (N = 178)
*Because of its problematic distribution and small standard deviation, 
this BDI-II item was not included in the network analyses
Item Abbreviation Baseline Week 8
Mean SD Mean SD
Sadness SAD 1.4 0.8 0.5 0.6
Pessimism PES 1.4 0.8 0.7 0.7
Past failure FAI 1.8 0.7 0.8 0.8
Loss of pleasure LPLE 1.8 0.7 0.9 0.8
Guilty feelings GUI 1.3 0.8 0.5 0.6
Punishment feelings PUN 1.0 1.1 0.3 0.7
Self-dislike DIS 1.9 0.8 0.9 0.9
Self-criticalness CRI 1.7 0.9 0.7 0.7
Suicidal thoughts or wishes* 0.7 0.6 0.2 0.4
Crying CRY 1.6 1.1 0.5 0.9
Agitation AGI 1.0 0.9 0.5 0.7
Loss of interest LINT 1.9 0.9 0.8 0.8
Indecisiveness IND 1.8 1.0 0.7 0.8
Worthlessness WOR 1.6 0.8 0.5 0.7
Loss of Energy LENE 1.7 0.8 0.9 0.8
Change in sleep SLE 1.4 1.1 0.8 0.9
Irritability IRR 1.5 0.9 0.5 0.7
Change in appetite EAT 0.9 0.9 0.6 0.7
Concentration difficulty CON 1.8 0.6 0.8 0.8
Fatigue FAT 1.9 0.9 0.9 0.8
Loss of interest in sex LSEX 1.5 1.0 1.0 1.1
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group in the present study precludes insight into potential 
unique effects of SSRIs on network connectivity.
Another aim of this study was to examine changes in the 
order of strength centrality after 8 weeks of SSRI treatment. 
This would enable us to investigate if and how SSRIs change 
the way symptoms are related to one another. However, due 
to the small sample size, power was too low to detect sig-
nificant differences in the ordering of strength centrality at 
the two time points, especially at week 8. Indeed, correla-
tion stability coefficients (0.13) were lower than the rec-
ommended lower bound of 0.25 [35], suggesting that our 
estimation of the ordering of the centrality of symptoms 
may be less reliable. Therefore, interpretation of the order 
of symptoms remains speculative.
However, at baseline, some symptoms appear to be sig-
nificantly more central than others, indicating they are more 
strongly connected. Indeed, our finding that loss of energy 
had the highest strength centrality at baseline, significantly 
higher than nine other symptoms, is not completely sur-
prising. The high centrality of loss of energy in depressed 
patients has been found in other network studies [11, 13, 
42] and is in line with evolutionary theory, which proposes 
that depressive symptoms force an individual to conserve 
energy during adverse situations and reallocate it to solv-
ing the problem [43, 44]. In a prospective study, strength 
centrality of fatigue was a strong predictor of depression 
onset [42]. It is speculated that by targeting and reducing 
central symptoms, because of its strong connections, other 
symptoms are reduced in parallel, which may prove to be a 
valuable treatment strategy [45]. However, other explana-
tions may be possible as well, such as that highly central 
symptoms are part of the same latent variable (for example, 
loss of energy and fatigue may tap into the same construct), 
and because they are so strongly interconnected, all esti-
mates of strength centrality are biased [46].
The centrality of loss of energy decreased relative to the 
other symptoms at week 8; instead, loss of interest became 
the most central symptom. However, since strength cen-
trality was not significantly higher for loss of interest than 
any other symptom, we cannot conclude with certainty 
that it is indeed more central. If our findings are repli-
cated, a speculative thought may be that SSRIs weaken 
the connections of energy loss to other depressive symp-
toms, thereby alleviating depression. The finding that loss 
of interest became the most central symptom may sug-
gest that if anhedonia is still present after treatment, other 
symptoms are still present too. Indeed, studies have shown 
that symptoms of anhedonia are resistant to SSRI treat-
ment and predictive of poorer outcome [47–49]. SSRIs 
do not appear to target dopamine systems; thus they might 
not target symptoms related to the experience of positive 
affect and reward [50, 51]. Speculatively, SSRIs may sever 
the links between symptoms related to negative affect and 











































Fig. 2  EBIC gLasso network of BDI-II symptoms before the start of 
treatment (left) and after 8 weeks of paroxetine treatment (N = 178). 
Note: Abbreviations can be found in Table  2. Green lines represent 
a positive association between two symptoms. The thicker the edge 
(line), the stronger the relationship between two symptoms. The 
color of the nodes represents the community the symptom belongs 
to; nodes with similar color belong to the same community. The pro-
portion of explained variance (predictability) can be derived from the 
blue ring surrounding the node
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other symptoms remain. However, power issues and lack 
of a comparison group prevented us from elucidating spe-
cific effects of SSRI treatment on the strength centrality 
of symptoms.
Important strengths of our study include the use of 
state-of-the-art network analysis techniques, our specific 
investigation of one type of SSRI, and the study design, 
which enabled us to compare symptom networks before 
and after treatment. However, our findings should also be 
considered in light of several limitations. First, because of 
insufficient power, we were not able to take advantage of 
the placebo controls. Thus, any observed change may not 
be due to specific effects of the SSRI. Second, our sam-
ple size was suboptimal for a network analysis with such 
a large number of nodes, limiting insight into potential 
significant differences in symptom centrality. Third, the 
Fig. 3  Bootstrapped differ-
ence tests of strength central-
ity between nodes within the 
baseline network and the week 
8 network (N = 178). Note: 
Gray boxes indicate nodes that 
did not significantly from one 
another and black boxes indicate 
nodes that do differ significantly 
from one another. White boxes 
show the value of strength 
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positive skewness of the individual BDI-II items at week 
8 may have affected our results [32]. Future investigations 
into how skewness should be addressed in Gaussian net-
work models are warranted. Fourth, the specific charac-
teristics of our sample may have limited generalizability. 
Also, BDI-II sum score was used as an inclusion crite-
rion. Using the same instrument for inclusion and network 
analyses may have influenced the results [52], although we 
expect this effect to be small given that participants were 
also selected based on other instruments (HRSD, SCID-I). 
Given these limitations, future studies with larger sample 
sizes and placebo controls are necessary before conclu-
sions on the effects of SSRI on symptom interrelations 
can be drawn.
A final note on the interpretation of cross-sectional net-
works should be made considering recent concerns on the 
replicability of networks [53]. Indeed, the network litera-
ture will benefit from insight into whether reported network 
structures replicate across data sets before clinical inferences 
can be made. First attempts to study replicability have thus 
far yielded conflicting results (see [53–55]). Furthermore, 
cross-sectional networks face the limitation that they may 
only reveal the co-occurrence of symptoms, not how they 
follow each other over time [56], and it has been questioned 
whether cross-sectional group-level associations can be gen-
eralized to the level of the individual [57]. Our findings, 
therefore, need to be replicated, preferably by designs that 
offer more insight into the temporal dynamics of relation-
ships between symptoms at the individual level [58]. Specifi-
cally, such temporal data enable investigation into changes in 
which symptoms precede changes in other symptoms. Con-
sequently, one can be more certain about the direction of 
change, allowing the identification of symptoms that precede 
change in other symptoms [13]. We, therefore, consider this 
study an exploration of the possibilities of applying the net-
work approach to uncover novel insights into the way anti-
depressant treatment works. Follow-up studies are required 
to examine whether central symptoms and changes over time 
generalize to the dynamics of symptoms taking place within 
individual patients.
To our knowledge, this was the first study to examine 
changes in symptom interrelations and their centrality after 
8 weeks of SSRI treatment. Our findings demonstrated an 
increase in the interrelations between depressive symp-
toms after SSRI treatment, which adds to previous research 
reporting increased connectivity after symptom severity 
decreased. The current findings highlight the potential of 
the network approach in providing insight into the work-
ing mechanisms of SSRIs on the interrelations between 
depressive symptoms, which should be explored in future 
research.
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